Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

This IND filing follows the prestigious award ... Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when ...

This IND filing follows the prestigious award of a grant as ... Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory ...

RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR ... CSPC will work collaboratively to file an IND application with the USA Food & Drug Administration (FDA) to execute the ...

RB-164 employs a novel Fc-silenced monoclonal antibody targeting ROR-1 ... Radiance and CSPC will work collaboratively to file an IND application with the USA Food & Drug Administration (FDA) to ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).